FRANKFURT, Jan 22 (Reuters) - AstraZeneca said initial
deliveries to the European Union of the COVID-19 vaccine it is
developing with Oxford University will fall short of the
targeted volumes because of a glitch in production.
"Initial volumes will be lower than originally anticipated
due to reduced yields at a manufacturing site within our
European supply chain," a company spokesman said in a written
statement, declining to provide details.
"We will be supplying tens of millions of doses in February
and March to the European Union, as we continue to ramp up
production volumes," he added. He would not provide the initial
volume target.
A decision on the EU's regulatory approval of the compound
has been expected for the end of January.
(Reporting by Ludwig Burger
Editing by Edward Taylor)
Astrazeneca (AZN)
